Patent intelligence · US
US 8895055
Telodendrimer nanodiscs without apolipoprotein
Telodendrimer nanodiscs without apolipoprotein
Patent details — US 8895055
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 25, 2014
- Expiration
- Nov 20, 2034
- Claims
- 21
- CPC classes
- A61K, A61K31/7048, A61K9/1271, A61K9/1275
Quick answer
US 8895055 (Telodendrimer nanodiscs without apolipoprotein) is held by The Regents of the University of California. Status: granted. Granted Nov 25, 2014. Expires Nov 20, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/7048, A61K9/1271, A61K9/1275
More from The Regents of the University of California
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 8895055?
US 8895055 (Telodendrimer nanodiscs without apolipoprotein) is held by The Regents of the University of California. Status: granted. Granted Nov 25, 2014. Expires Nov 20, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8895055?
The Regents of the University of California is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 8895055 expire?
Our index shows an expiration date of Nov 20, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.